← Surfer · Coach hub

Coach — Metabolic Hypothesis of Dermatology

Hair and skin are expensive to keep. Pigment, the thickness of each hair, barrier lipids, collagen turnover, and a healthy glow all spend energy. The working hypothesis here is that when mitochondria cannot meet that cost, the skin does not fail at random. It rations, giving up the most expensive outputs first, and when the shortfall is severe and long-lasting, the same ladder leads toward skin cancer.

Safety before ideas

This essay does not replace a dermatologist. The extended report opens with its own warning: "Skin: This does not replace a dermatologist. Changing moles, non-healing sores, or suspected skin cancer need prompt in-person evaluation. This page is not a license to burn in the sun."

A few more cautions follow. Red flags are referred, not reinterpreted: a changing mole or a sore that will not heal goes to a dermatologist promptly. Cancer care stays with cancer specialists, and the report is clear that "Surgery, destruction, targeted therapy, and immunotherapy remain essential tools for controlling existing neoplastic populations." Biologics, steroids, and JAK inhibitors are not stopped because an essay reframed the biology, and tapering an anti-androgen is a clinical decision, not a do-it-yourself plan. Severe restriction or unsupervised prolonged fasting can harm hair follicle stem cells even while blood tests "improve," so gradual restoration is safer than heroic fasting for this tissue. Nothing here promises reversal past the limits described below.

Rationing in rank order

The report starts with cost. Melanocytes in growing hair follicles are among the most metabolically active cells in the skin: making melanin is an oxidative process, and the cells must produce pigment, neutralize its by-products, and pass pigment granules to neighboring cells all at once. Rapidly dividing follicle cells add more demand. When mitochondrial capacity declines, the report proposes that the follicle sheds functions in order. Pigment goes first, because it is a highly visible signal of surplus but not needed for the hair to exist; the result is graying. Then shaft diameter and the length of the growth phase shrink, and finally density and quality fall.

One clarification helps. The hair you can see is not alive: the shaft is made of dead cells packed with keratin and has no metabolism of its own. The switch from living to dead cells happens low in the follicle, near the bulb, where the nucleus and then, it appears, the mitochondria are broken down. The energy spending happens in the living follicle below the skin. That is why, as far as small studies in men show, cutting or shaving hair does not appear to make the follicle grow faster or thicker, and why ordinary shampoo and conditioner work on the surface of the hair and scalp rather than on the follicle’s energy supply. Unlike a nerve fiber, which stays alive along its length, the hair shaft cannot be fed after it is made; in this view it is a record of the follicle’s budget at the time it grew.

Pattern follows the same logic. Temples and the front of the scalp often gray before the crown or the back of the head, and patterned hair loss thins the temples and crown preferentially where androgen sensitivity meets an energy shortfall. The skin itself shows the same budget at work: dull or uneven tone, thinner dermis, earlier wrinkling, a weaker barrier, and acne-prone or persistently inflamed skin are, in this view, parallel readings of one mismatch rather than a stack of separate problems.

Some inflammatory and autoimmune conditions fit as later or more extreme expressions. In the report's reading, vitiligo, alopecia areata, and some forms of rosacea may arise when mitochondrial quality control in melanocyte or follicle niches collapses, damage signals from mitochondria rise, and the immune system targets cells that were already stressed. Patterned hair loss also often travels with insulin resistance, abdominal fat, and higher blood pressure. The report cites supporting observations: defects in mitochondrial DNA maintenance cause premature hair loss in animal models and are proposed to cause premature graying, and depleting mitochondrial DNA in mice causes hair loss and wrinkled, inflamed skin that reverse when mitochondrial function is restored.

Familiar tools, repositioned

Anti-androgens, such as 5-alpha-reductase inhibitors and androgen-receptor blockers, slow miniaturization for many people. In this hypothesis, DHT magnifies energy rationing in androgen-sensitive scalp, and high insulin can raise free androgen by lowering SHBG, so the drug manages an amplifier rather than restoring mitochondrial headroom. Benefits often plateau, and rebound is possible if the mismatch was never corrected. When insulin sensitivity and inflammation improve first, the report suggests that a lower dose or intermittent use may suffice, as a judgment for the prescribing physician.

Retinoids and laser resurfacing work by forcing faster turnover or controlled injury and repair, and both raise demand on skin cells. In the report's reading, they are load amplifiers, not engine repair. Irritation and poor remodeling are expected when capacity is already short, and the report expects less retinoid irritation and more durable collagen when capacity improves first. Steroids, biologics, and JAK inhibitors remain sometimes essential for flares and destructive disease. They can quiet the dashboard while the underlying damage signals and barrier failure continue, and the report's hypothesis is that a calmer inflammatory tone and a tighter barrier would shorten courses and blunt rebound.

Skin cancer at the far end of the ladder

The report places skin cancer at the end of the same hierarchy, using the two-step sequence from its cancer report. In step one, keratinocytes or melanocytes under cumulative ultraviolet load, aging, insulin resistance, or inflammation lose oxidative capacity and switch to a primitive glycolytic rescue. That is not yet cancer. In step two, natural selection within the stressed population favors subclones that are best at that rescue, and mutations that help them persist are retained. Actinic keratoses, squamous dysplasia, and dysplastic nevi are, in this reading, visible intermediate stages: tissue that has taken the first step but not the second.

From this the report draws a practical point. Removing an individual precancerous lesion removes the visible lesion but, in its view, does not restore the capacity of the surrounding field, so new lesions keep appearing. It reads late melanoma recurrence, sometimes years after wide excision, the same way, and states its hypothesis carefully: "metabolic restoration concurrent with or following definitive local therapy should reduce late recurrence risk beyond what local control alone can achieve." That is a prediction to test, not a treatment claim. Surgery, destruction, targeted therapy, and immunotherapy remain essential for existing cancers. The full discussion is in the report's section on skin cancer.

What can recover, and what cannot

The report predicts real plasticity while the underlying structures remain. Individual hairs have been documented graying and then fully repigmenting along the same shaft, in step with a reduction in psychological stress. In cultured human scalp follicles that still contain melanocytes, inhibiting mTORC1 restarted pigment production. Hair diameter can recover while the follicle's base and stem-cell niche remain competent, and dermal quality can improve while fibroblasts can still invest. Correcting a documented deficiency of vitamin B12, copper, or iron can return pigment in newly growing hair. Those are conditional recoveries, not a reason for a gray-hair supplement stack.

The hard stops matter as much. A follicle whose pigment stem cells are depleted cannot repigment. A follicle that has converted to fine vellus hair or dropped out through fibrosis cannot be restored. Cancer clones that have become locked and invasive are beyond this kind of restoration. Past those thresholds, the realistic goal becomes stabilization and the quality of what remains. Objective tracking helps tell genuine change from a temporary shedding cycle: serial photographs, trichoscopy for hair diameter and density, dermoscopy of pigmented lesions, and simple metabolic markers such as fasting insulin, HOMA-IR, grip strength, and inflammatory indices.

Light as a dose with a window

The report treats sunlight as a direct mitochondrial input. Red and near-infrared light act on cytochrome c oxidase, part of the electron transport chain, increasing ATP production and causing a small, hormetic rise in reactive oxygen species that switches on repair and renewal. Morning and late-day sun is relatively rich in red and near-infrared light; midday sun carries the most ultraviolet, with both the greatest potential for vitamin D and the greatest DNA-damage load. The report's goal is matching, not maximizing or minimizing: non-burning exposure suited to skin type, latitude, and season. Chronic avoidance removes a signal; repeated burning drives the first step toward cancer.

On sunscreen, the report is careful. The so-called sunscreen paradox, in which frequent users have higher skin cancer rates, is "real but almost certainly confounded," because people who use more sunscreen often spend more time in strong sun and reapply poorly. Randomized trials of proper daily use, notably the Nambour trial, reduced squamous-cell carcinoma and, in long-term follow-up, melanoma. "The paradox therefore does not prove that sunscreen causes cancer". When protection is needed to prevent a burn, the report prefers mineral blockers, non-nano zinc oxide and titanium dioxide, over chemical filters. For the eyes, it favors unfiltered morning outdoor light, never looking directly at the sun, for the body clock, with protection when ultraviolet load is high, such as at midday, at altitude, or near reflective surfaces. Astaxanthin appears in the report as a membrane redox buffer that may modestly raise the UV dose needed to cause redness, an adjunct, not a sunscreen replacement, and red-light devices as tools for closing a gap, not replacements for outdoor light.

The other pillars are familiar. Fuel means animal proteins and fats with fermented, fermentable carbohydrates, better insulin sensitivity to raise SHBG and ease local DHT pressure, and repletion of documented deficiencies rather than megadoses of "hair vitamins." Strength means progressive resistance training, without the heroic energy deficit that taxes follicle stem cells.

Order of questions

The sequence is plain. First, urgent skin problems are referred. Then come the everyday foundations: food, meals in daylight with a real gap before sleep, consistent sleep, and progressive strength. Then light is handled with sense: non-burning sun matched to the time of day, mineral protection when a burn would otherwise follow, and morning light to the eyes. Then measurement comes before another cream or procedure. Only then are the dashboard tools repositioned with the treating physician: anti-androgens, retinoids, lasers, immune agents, and cancer control. Skin and scalp quality also work as everyday recovery readings, since late meals, chronic sleep debt, and poor food tend to show in the mirror.

Several errors are worth naming. One escalates anti-androgens or chronic steroids forever while food, light, and strength stay untouched. Another treats hormetic sun as permission to blister, and its mirror image deletes every ray of sun in the name of protection. Others promise full pigment return after stem cells are gone, or a cured field after excision alone, or chase aggressive fasting that quietly harms follicle stem cells.

Limits and related topics

This is a working hypothesis within a broader metabolic philosophy of medicine. It does not prove disease reversal, does not replace dermatology or cancer care, and does not create a treatment plan. Genetic androgen sensitivity and stem-cell reserve set ceilings. The report states that it "is a hypothesis within the metabolic philosophy of medicine, not medical advice. Individual evaluation by a qualified physician remains essential."

Some topics continue elsewhere. The two tool sections above, on familiar tools and on what can recover, carry the practical core. Skin cancer is covered in depth in the report's skin cancer section. Dry eye and the eye's surface are discussed in a metabolic hypothesis of ocular surface disease. Leprosy, whose home is the immune chapter, also belongs here because it shows in the skin and nerves; its essay is the metabolic hypothesis of leprosy. Like every illness on this site, it is never framed as a sin or a moral failure. The other essays are listed in the essay index. For the full argument, read the extended report on dermatology. The short version is in the lessons. Talk with your own physician before changing medications or supplements.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 31, 2026.

See the notice at the top of this page. Working hypothesis, not medical advice.